CASP-AID’s APPROACH
Therapies for Alzheimer disease have failed to deliver meaningful outcomes for patients. Unlike these approaches, Casp-Aid aims to repair neurons responsible for cognitive impairment with a distinctly novel pathway.
Our first-in-class compound (CIM765) Inhibits Caspase-1 to Address Neuronal Dysfunction in Cognitive Impairment
treatment with cim765 Normalizes Episodic and Spatial Memory in Mouse Model of Cognitive Impairment
Memory Function Restored in Alzheimer Mouse Model Following Caspase-1 Inhibition
Key Pre-Clinical Outcomes:
- Continued treatment with CIM765 sustains normalized cognition
- Discontinuation of treatment reinstates cognitive impairment
- Resuming treatment improves/normalizes cognition
cim765 has a well-established safety profile and is preparing to enter a Phase 2 trial for alzheimer disease
- Cognitive Impairment Modulator (CIM765) is a first-in-class symptom- and disease-modifying small molecule new chemical entity
- Established safety in 4 prior FDA Phase II studies
- Optimal profile for CNS: (i) brain penetrant; (ii) high selectivity (and strong potency) for Caspase-1; (iii) oral administration
- Completed animal toxicology and human safety data in hand
- CMC data package with cGMP-manufactured API in hand